Press Releases

IDENTOS marks a decade of innovation and growth, reflecting on key achievements as it charts a grand course for the future

TORONTO--(BUSINESS WIRE)-- IDENTOS Inc., a leader in facilitating seamless access to healthcare and government digital services, proudly commemorates a decade of innovation, growth, and unwavering commitment to excellence. Founded in 2014 by Mike Cook and Hamid Arabzadeh, IDENTOS has emerged as a trusted partner for security software and IT... (continue reading...)

LONDON, UK / ACCESSWIRE / May 21, 2024 / Ecora Resources PLC (LSE:ECOR)(TSX:ECOR) announces that on 21 May 2024, it purchased 300,000 ordinary shares of 2p each in the Company (the "Shares") on the London Stock Exchange through Peel Hunt LLP, in accordance with the terms of its share buyback programme announced on 27 March 2024 (the "Programme"). The shares acquired will be held in treasury.

Date of purchase:

21 May 2024

Aggregate number of ordinary shares purchased:

... (continue reading...)

TEDA TIANJIN, China--(BUSINESS WIRE)-- Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe. Asymchem will continue to operate the site in Sandwich, Kent, as a clinical small molecule... (continue reading...)

MCLEAN, Va., May 21, 2024 /PRNewswire/ -- Steampunk announced today that the company has been awarded a Basic Ordering Agreement (BOA) with the United States Department of Agriculture (USDA).

The BOA was awarded as part of the STRATUS program for cloud integration and development support services. The STRATUS program aims to accelerate cloud adoption by... (continue reading...)

– Enrollment completed within planned timeframe of 14 months –

– IGV-001 granted Fast Track designation by U.S. FDA –

– $35 million financing completed in 2024 to fund operations beyond expected Phase 2b data readout in mid-2025 –

PHILADELPHIA--(BUSINESS WIRE)-- Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized,... (continue reading...)